LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
promising findings on the in vitro and in vivo activity of microRNA-targeted
therapeutics against cancer developed on the basis of its proprietary Locked
Nucleic Acid (LNA) Drug Platform. In both in vitro and in vivo models
Santaris Pharma’s cancer targeted LNA-antimiR(R)’s demonstrated outstanding
recognition and inhibition of disease-associated microRNAs due to their high
specificity and affinity. The findings were presented this week at the AACR
Meeting in
(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )
“Santaris Pharma has made significant progress in advancing a rich
pipeline of clinical and preclinical drug candidates targeting disease
related RNAs, including microRNAs,” said Henrik 0rum, Santaris Pharma’s Chief
Scientific Officer. “These results are another demonstration of the fact that
our small, single-stranded oligonucleotides have great potential in relation
to the development of microRNA targeting therapeutics within a range of
disease areas.”
Santaris Pharma is a leader within microRNA research and is collaborating
with scientists world-wide to exploit the advantages of the LNA chemistry to
design and develop effective and safe antimiRs against a broad range of
diseases, including cancer.
Santaris Pharma (founded in 2003) is a privately held clinical stage
biopharmaceutical company developing new classes of RNA medicines targeting
disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The
Company’s own research and development activities focus on microRNAs,
infectious diseases and metabolic disorders. Santaris Pharma is leveraging
its highly effective and efficient Drug Discovery Engine to generate lead LNA
drug candidates against a broad array of disease targets selected by
strategic partners. The Company and its corporate partners currently have
four compounds in clinical development and a full pipeline in late
preclinical development. Santaris Pharma has since its inception raised
nearly
For further information please contact
Randi Krogsgaard, Director, Corporate Communications
Direct phone +45-4517-9879
Cell: +45-20488384
E-mail: rmk@santaris.com
http://www.santaris.com
SOURCE Santaris Pharma A/S